Inventor
RALF HOSSE
Inventor
CH
Overview
Patents· 16 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07KPeptides31%
C12NMicroorganisms or enzymes6%
C12YEnzymes2%
PatentTitleYear
12,473,373Bispecific antibody molecules binding to CD3 and EGFRvIII202512,286,486Anti-FAP antibodies and methods of use202512,240,911Bispecific antibodies specific for OX40202512,215,155Antibodies binding to CD3 and CD19202512,139,553T cell activating bispecific antigen binding molecules202412,103,982T cell activating bispecific antigen binding molecules202411,952,421Bispecific antibodies against CD3EPSILON and ROR1202411,827,711Antibodies binding to NKG2D202311,787,873Bispecific HER2 antibodies and methods of use202311,780,920Antibodies binding to CD3 and CD19202311,672,858Bispecific antibody molecules binding to CD3 and TYRP-1202311,608,376Tumor-targeted agonistic CD28 antigen binding molecules202311,591,397Bispecific antibody molecules binding to CD3 and EGFRvIII202311,365,232Interleukin-2 fusion proteins and uses thereof202211,332,545Anti-FAP antibodies and methods of use202211,214,622Antibodies specific for DR5 and methods of use2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to ROCHE GLYCART AG (4)· patent assignee history
2022–2025Based in CH· patent location history
2023–2025Patents assigned to HOFFMANN LA ROCHE (11)· patent assignee history
2024Patents assigned to BRISTOL MYERS SQUIBB CO (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HOFFMANN LA ROCHE | 11 | 2023–2025 |
| ROCHE GLYCART AG | 4 | 2022–2025 |
| BRISTOL MYERS SQUIBB CO | 1 | 2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| CH | 16 | 2022–2025 |